NASDAQ · Medical - Devices

Bluejay Diagnostics, Inc. (BJDX) Stock

$0.82 +0.00% NASDAQ: BJDX Healthcare

Valuation

MetricValue
Price$0.82
Market Cap$843913
P/E Ratio-0.07
P/B Ratio0.18
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$16.68
52-Week Low$0.76
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-125.01%
ROA-63.04%
ROCE-78.19%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio5.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-3.0M$-9.0M$-10.0M$-7.0M$-7.0M
Net Profit$-4.0M$-9.0M$-10.0M$-8.0M$-7.0M
EPS$-118.68$-292.88$-290.48$-456.76$-15.25
Op Margin—-3741.5%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$21.0M$14.0M$5.0M$7.0M$7.0M
Total Liabilities$1.0M$2.0M$2.0M$1.0M$1.0M
Cash$19.0M$10.0M$2.0M$4.0M$5.0M
Borrowings$0$0$0$0$0

Latest News

Bluejay Diagnostics Completes Enrollment in SYMON-II Clinical Validation Study MT Newswires · Jul 21, 2026 Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study GlobeNewswire · Jul 21, 2026 BC-Most Active Stocks Associated Press · Jul 7, 2026 Top Premarket Gainers MT Newswires · Jul 7, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules GlobeNewswire · Jun 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-8.0M$-8.0M$-8.0M$-6.0M
Investing Cash Flow$0$-2.0M$-1.0M$-1.0M$0
Financing Cash Flow$-1.0M$0$1.0M$-2.0M$-1.0M
Net Cash Flow$18.0M$-9.0M$-8.0M$2.0M$1.0M
Free Cash Flow$-4.0M$-9.0M$-9.0M$-8.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA1.21
FCF Yield-737.81%
Quick Ratio4.64
Interest Coverage-19027.83
Return 1Y-79.42%
Return 3Y-99.98%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCTXZBriaCell Therapeutics Corp. Warrant $0.10 +8.47% -0.30 $188186 0.00%
ELABPMGC Holdings Inc. $3.07 -1.92% 0.00 $1.39M 0.00%
MLECMoolec Science SA $2.60 -37.95% -0.02 $1.89M 0.00%
MSPRMSP Recovery, Inc. $0.01 +66.67% 0.00 $137744 0.00%
NKGNNKGen Biotech, Inc. $0.06 +0.00% -0.04 $7.84M 0.00%

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. is led by CEO Indranil Dey, employs 7 people, headquartered in US, publicly traded since 2021.

Bluejay Diagnostics, Inc. (BJDX) stock trades at $0.82 with a market capitalization of $843913. The stock is valued at a price-to-earnings (P/E) ratio of -0.07, price-to-book of 0.18, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.76 and $16.68, and currently trades 95.1% below its 52-week high.

On profitability, Bluejay Diagnostics, Inc. generates a return on equity (ROE) of -125.01%, return on capital employed of -78.19%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1175.60 +0.51% JNJ Johnson & Johnson $259.92 +1.34% ABBV AbbVie Inc. $276.17 +1.38% MRK Merck & Company, Inc. Common Stock (new) $146.13 +2.63% UNH UnitedHealth Group Incorporated Common Stock (DE) $382.39 +3.08% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $659.63 +1.17% AMGN Amgen Inc. $417.07 +2.36% GILD Gilead Sciences, Inc. $150.92 +2.60% ABT Abbott Laboratories $99.12 +0.64% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides